🔗 Share this article America and Britain Strike Duty-Free Pact on Pharmaceuticals. Conceptual image of drug trade. The UK and US have agreed to a key bilateral deal that will keep no tariffs on UK drug products going into the American market. Key Provisions of the Pact In exchange for the tariff guarantee, the UK has committed to boost expenditure on medicines through the National Health Service (NHS). This commitment secures that tariffs on these key exports will stay at zero for a duration of the next three years. This agreement follows recent warnings to dramatically increase duties on patented drug products, with potential rates mentioned as high as one hundred percent. "This agreement with the Britain reinforces the global environment for new treatments and establishes long-overdue balance to American-British pharmaceutical trade," a release said. Economic Importance Medicines are one of the UK's most significant exports to the US, which is easily the primary buyer for large companies like GSK and AstraZeneca. Export figures show that in the year prior to last September, the UK exported drugs valued at billions to the US. This value represented 17.4% of total UK exports in that period. "This deal safeguards work, increases funding and paves the way for the UK to emerge as a international leader for medical research," a government official stated. Specific UK Commitments The agreement entails several specific pledges from the UK: Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new treatments to be unaffordable by a quarter. Increased NHS Spending: There is a target to double overall health service expenditure on medicines from 0.3% of the national economy to 0.6% over the following ten-year period. Payback Limit: The percentage drug companies must pay back to the NHS to stay within budget will be limited at fifteen percent. In the past, repayments exceeded 20%. Recent Tensions The pact takes place against a ongoing tension between the drug companies and the UK government over medicine costs and approval rates. This friction were heightened by arguments that American consumers were charged significantly more for the identical medicines than people in the Britain and the EU. Over the last 18 months, several large manufacturing plans in the UK have been halted or cancelled, while major investments have been announced toward projects in the United States. The Science Minister stated that the NHS needed to increase expenditure on medicines, noting that its spending on drugs had shrunk as a percentage of its total funding over the previous ten-year period.
Conceptual image of drug trade. The UK and US have agreed to a key bilateral deal that will keep no tariffs on UK drug products going into the American market. Key Provisions of the Pact In exchange for the tariff guarantee, the UK has committed to boost expenditure on medicines through the National Health Service (NHS). This commitment secures that tariffs on these key exports will stay at zero for a duration of the next three years. This agreement follows recent warnings to dramatically increase duties on patented drug products, with potential rates mentioned as high as one hundred percent. "This agreement with the Britain reinforces the global environment for new treatments and establishes long-overdue balance to American-British pharmaceutical trade," a release said. Economic Importance Medicines are one of the UK's most significant exports to the US, which is easily the primary buyer for large companies like GSK and AstraZeneca. Export figures show that in the year prior to last September, the UK exported drugs valued at billions to the US. This value represented 17.4% of total UK exports in that period. "This deal safeguards work, increases funding and paves the way for the UK to emerge as a international leader for medical research," a government official stated. Specific UK Commitments The agreement entails several specific pledges from the UK: Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new treatments to be unaffordable by a quarter. Increased NHS Spending: There is a target to double overall health service expenditure on medicines from 0.3% of the national economy to 0.6% over the following ten-year period. Payback Limit: The percentage drug companies must pay back to the NHS to stay within budget will be limited at fifteen percent. In the past, repayments exceeded 20%. Recent Tensions The pact takes place against a ongoing tension between the drug companies and the UK government over medicine costs and approval rates. This friction were heightened by arguments that American consumers were charged significantly more for the identical medicines than people in the Britain and the EU. Over the last 18 months, several large manufacturing plans in the UK have been halted or cancelled, while major investments have been announced toward projects in the United States. The Science Minister stated that the NHS needed to increase expenditure on medicines, noting that its spending on drugs had shrunk as a percentage of its total funding over the previous ten-year period.